Citigroup Lowers Illumina Revenue Forecast | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Citigroup today lowered revenue estimates for Illumina for the second quarter and for full-year 2011, saying that revenues from a trade-in program for the HiSeq 2000 next-generation sequencing platform would not be a "significant contributor" to total revenues.

Last year, Illumina launched a trade-in program offering customers the opportunity to trade in their Genome Analyzers for the new HiSeq 2000 system.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.